Skip to Main Content
Skip Nav Destination

Telisotuzumab Vedotin Is Active in MET-Overexpressing Non-Squamous NSCLC

June 18, 2024

Major Finding: In the phase 2 LUMINOSITY trial of telisotuzumab vedotin monotherapy in previously treated advanced EGFR-wildtype non-squamous NSCLC, the overall response rate was 28.6%.

Concept: A trend toward a higher overall response rate was observed in patients whose tumors had high MET expression.

Impact: Telisotuzumab vedotin may benefit a patient population for whom no MET-targeted therapies are currently available.

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal